Permethrin

Karma Yousef
Pioneers Baccalaureate School-Nablus, Palestine
March 13, 2016
ABSTRACT
This paper will discuss the drug Permethrin, its uses, side effects
and purpose. As well as it will have the history of the drug and, its
presents in the world and in Palestine.
INTRODUCTION
Permethrin is a beneficial drug to a certain extent. In 1974, the
Rothamsted team discovered permethrin, which turned out to be
resistant to degradation by light and air. This made them suitable
for agriculture but not suitable for humans considering them
toxics. It is used in many countries but banned in others.

METHODS
1

 Candy
Sticks

DISCUSSION
Name of the Drug:
Permethrin. Other names: Nix Dermal Cream, Elimite, and
Acticin 1
Chemical Makeup
Its chemical makeup is written as: C21H20Cl2O3
Chemical Structure2

Purpose of the Drug

2

It is a topical cream that is used to treat scabies. Scabies is a

skin disease caused by a tiny insect called mite. Permethrin is
neurotoxin that works by paralyzing nerves in respiratory
muscles of scabies causing their death. 3
Side Effects of the Drug
Skin irritation, including itching, swelling, and redness, may
occur with scabies and temporarily worsen after treatment with
Permethrin. Very severe burning or stinging may also occur. 4
Presence in the World
It is on the World Health Organization's List of Essential
Medicines, the most important medications needed in a
basic health system. This means that it is found all over the
world. 5
Presence in Palestine
It is found in all the pharmacies in Palestine
ACKNOWLEDGEMENTS
I would like to thank Miss Meha for teaching me how to write this
paper. Thank the school for providing me with the space to do my
model; as well as my parents for providing me with the materials.
LITERATURE CITED

1
2
3
4

http://www.drugs.com/ingredient/permethrin.html
https://commons.wikimedia.org/wiki/File:Permethrin_structure.png
https://www.nlm.nih.gov/medlineplus/druginfo/meds/a698037.html
http://www.rxlist.com/elimite-drug/patient-images-side-effects.htm

5 http://apps.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf?ua=1